דטסקאן

Country: Iżrael

Lingwa: Ebrajk

Sors: Ministry of Health

Ingredjent attiv:

IOFLUPANE

Disponibbli minn:

ELDAN ELECTRONIC INSTRUMENTS CO LTD

Kodiċi ATC:

V09AB03

Għamla farmaċewtika:

תמיסה להזרקה

Kompożizzjoni:

IOFLUPANE 74 MBQ/ML

Rotta amministrattiva:

תוך-ורידי

Tip ta 'preskrizzjoni:

מרשם נדרש

Manifatturat minn:

GE HEALTHCARE B.V., THE NETHERLAND

Grupp terapewtiku:

OTHER DOPAMINERGIC AGENTS

Żona terapewtika:

IODINE IOFLUPANE (123I)

Indikazzjonijiet terapewtiċi:

Datscan is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum: - of patients with clinically uncertain Parkinsonian Syndromes in order to help differentiate Essential Tremor from Parkinsonian Syndromes related to idiopathic Parkinson's Disease Multiple System Atrophy and Progressive Supranuclear Palsy. - Datscan is unable to discriminate between Parkinson's Disease Multiple System Atrophy and Progressive Supranuclear Palsy. - To help differentiate probable dementia with Lewy bodies from Alzheimer's disease. Datscan is unable to discriminate between dementia with Lewy bodies and Parkinson's disease dementia

Data ta 'l-awtorizzazzjoni:

2014-11-30